Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Theravance Announces Positive Early Data On JAK Inhibitor

By Zacks Investment ResearchStock MarketsSep 09, 2019 11:46PM ET
www.investing.com/analysis/theravance-announces-positive-early-data-on-jak-inhibitor-200463406
Theravance Announces Positive Early Data On JAK Inhibitor
By Zacks Investment Research   |  Sep 09, 2019 11:46PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Theravance Biopharma, Inc. (NASDAQ:TBPH) announced promising outcomes in the areas of safety and tolerability, pharmacokinetics and preliminary pharmacodynamic activity from a phase I study on its investigational, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor, TD-8236. The candidate is being developed for the treatment of inflammatory lung diseases with minimal systemic exposure.

The early-stage randomized, placebo-controlled study on TD-8236 consists of two parts. The first evaluated the candidate in single ascending doses (SAD) (up to 4500 mcg) in healthy patients while the second evaluated TD-8236 in multiple ascending doses (MAD) (up to 4000 mcg), which is administered as a once-daily dose to patients with mild asthma for seven consecutive days.

Initial data from the study showed that in both regimens, TD-8236 was well tolerated with no evidence of local irritation or bronchoconstriction in the given patient population. Also, none of the patients discontinued the treatment and there were no serious adverse side effects reported.

Importantly, the candidate produced the desired biological activity in the target patient population as it led to reduction in fractional exhaled nitric oxide (FeNO) in mild asthma patients who had elevated levels of FeNO. Treatment with TD-8236 also resulted in minimal systemic exposure.

Shares of Theravance were up almost 1.4% post this news on Monday. However, the stock has declined 14.6% so far this year against the industry’s increase of 6.3%.

TD-8236 is particularly designed as a dry-powder inhaler for the lungs with minimal systemic exposure. Following positive results from this study, Theravance has initiated a Part C extension portion of the phase I study on TD-8236, which will assess a range of additional biomarkers in patients with more severe asthma. The company also plans to initiate a lung allergen challenge phase II study on the candidate to provide additional insights in the days ahead.

We would like to remind investors that last November, Theravance dosed the first patient in the phase I study on TD-8236. It is the second JAK inhibitor discovered by Theravance.

Another JAK inhibitor in Theravance’s portfolio is TD-1473, which is being developed for the treatment of inflammatory intestinal diseases. The candidate is currently being evaluated in a phase IIb/III study for treating moderate-to-severe ulcerative colitis and in a phase II study for Crohn’s disease. The company has a collaboration agreement with Johnson & Johnson’s (NYSE:JNJ) subsidiary Janssen for developing TD-1473.

Theravance plans to report data from the phase IIb portion of the ulcerative colitis and phase II Crohn's disease studies on TD-1473 by late 2020.

Zacks Rank & Other Stocks to Consider

Theravance currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the same sector include Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and FibroGen, Inc (NASDAQ:FGEN) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cumberland Pharmaceuticals’ earnings estimates have moved 8.1% north for 2019 and 6.5% for 2020 over the past 60 days.

FibroGen’s loss per share estimates have been narrowed 57.5% for 2019 and 64.2% for 2020 over the past 60 days.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Johnson & Johnson (JNJ): Free Stock Analysis Report

FibroGen, Inc (FGEN): Free Stock Analysis Report

Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report

Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report

Original post

Zacks Investment Research
Theravance Announces Positive Early Data On JAK Inhibitor
 

Related Articles

Theravance Announces Positive Early Data On JAK Inhibitor

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email